Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page revision label has been updated from v3.5.2 to v3.5.3. This reflects a site/version metadata refresh rather than a change to the clinical study information presented.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedAdded new trial sites: Wrocław, Poland (51-685) and Lviv, Ukraine (79029), and added the collaborator 'Neurofocus LLC'. Removed outdated site entries for Wroclaw (51-685), Lviv in Chernihiv Governorate (79007), and the MNE Lviv Territorial Medical Association Clinical Hospital for Palliative Care.SummaryDifference0.3%

- Check50 days agoChange DetectedAdded Naples, Campania, Italy, 80138 as a study site and removed Napoli, Campania, Italy, 80138. Updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision: v3.4.3 was added and the previous Revision: v3.4.2 was removed.SummaryDifference0.0%

- Check86 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.